I think the most underestimated challenge in the wake of early detection is that of emotional readiness. Communicating risk for Alzheimer's, especially through blood-based biomarkers or genetic results, might carry heavy psychological baggage that some patients may not embody, especially when preventive or therapeutic measures cannot yet be truly assured. Many patients still take the word "risk" to mean "destiny," which can cause identity shifts, stressed family relations, or early withdrawal from life planning. I frequently see cases as a psychologist where abiogeny translates into heightened anxiety, depression, or even near catastrophic thinking after individuals learn their risk status, particularly when clinicians inadvertently inform them without offering the proper emotional scaffolding. Before even considering talking about APOE genotyping or polygenic scores, clinicians should pause and assess the patient's emotional resilience, social supports, and expectations. I think neuropsychologists or genetic counselors ought to be present for these discussions; perhaps such professionals may be able to translate uncertainty into words patients can understand without panicking. On an ethical basis, for the time being, it remains a question not only of what we tell patients, but why, when, and how we tell them—and what type of psychological care is provided afterward.